Literature DB >> 20307540

NPC1L1 and cholesterol transport.

Jenna L Betters1, Liqing Yu.   

Abstract

The polytopic transmembrane protein, Niemann-Pick C1-Like 1 (NPC1L1), is enriched in the apical membrane of small intestine absorptive enterocytes where it mediates extracellular sterol transport across the brush border membrane. It is essential for intestinal sterol absorption and is the molecular target of ezetimibe, a potent cholesterol absorption inhibitor that lowers blood cholesterol in humans. NPC1L1 is also highly expressed in human liver. The hepatic function of NPC1L1 may be to limit excessive biliary cholesterol loss. NPC1L1-dependent sterol uptake seems to be a clathrin-mediated endocytic process and is regulated by cellular cholesterol content. Recently, NPC1L1 inhibition has been shown to have beneficial effects on components of the metabolic syndrome, such as obesity, insulin resistance, and fatty liver, in addition to atherosclerosis. Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307540      PMCID: PMC2909875          DOI: 10.1016/j.febslet.2010.03.030

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  91 in total

1.  Extracellular loop C of NPC1L1 is important for binding to ezetimibe.

Authors:  Adam B Weinglass; Martin Kohler; Uwe Schulte; Jessica Liu; Emmanuel O Nketiah; Anu Thomas; William Schmalhofer; Brande Williams; Wolfgang Bildl; Daniel R McMasters; Kevin Dai; Lindsey Beers; Margaret E McCann; Gregory J Kaczorowski; Maria L Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-05       Impact factor: 11.205

2.  Ezetimibe prevents cholesterol gallstone formation in mice.

Authors:  Silvia Zúñiga; Héctor Molina; Lorena Azocar; Ludwig Amigo; Flavio Nervi; Fernando Pimentel; Nicolás Jarufe; Marco Arrese; Frank Lammert; Juan F Miquel
Journal:  Liver Int       Date:  2008-08       Impact factor: 5.828

3.  Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.

Authors:  Helen H Wang; Piero Portincasa; Nahum Mendez-Sanchez; Misael Uribe; David Q-H Wang
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

4.  Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5/ABCG8.

Authors:  Weiqing Tang; Yinyan Ma; Lin Jia; Yiannis A Ioannou; Joanna P Davies; Liqing Yu
Journal:  J Lipid Res       Date:  2008-09-15       Impact factor: 5.922

5.  Kinetic imaging of NPC1L1 and sterol trafficking between plasma membrane and recycling endosomes in hepatoma cells.

Authors:  Nicole Hartwig Petersen; Nils J Faergeman; Nils J Faegeman; Liqing Yu; Daniel Wüstner
Journal:  J Lipid Res       Date:  2008-06-03       Impact factor: 5.922

6.  The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.

Authors:  Liang Ge; Jing Wang; Wei Qi; Hong-Hua Miao; Jian Cao; Yu-Xiu Qu; Bo-Liang Li; Bao-Liang Song
Journal:  Cell Metab       Date:  2008-06       Impact factor: 27.287

7.  Niemann-pick C1-like 1 mediates alpha-tocopherol transport.

Authors:  Kazuya Narushima; Tappei Takada; Yoshihide Yamanashi; Hiroshi Suzuki
Journal:  Mol Pharmacol       Date:  2008-04-10       Impact factor: 4.436

8.  Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice.

Authors:  Eric D Labonté; Lisa M Camarota; Juan C Rojas; Ronald J Jandacek; Dean E Gilham; Joanna P Davies; Yiannis A Ioannou; Patrick Tso; David Y Hui; Philip N Howles
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-21       Impact factor: 4.052

9.  Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.

Authors:  Mark A Valasek; Joyce J Repa; Gang Quan; John M Dietschy; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-21       Impact factor: 4.052

10.  Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.

Authors:  Shuqin Zheng; Lizbeth Hoos; John Cook; Glen Tetzloff; Harry Davis; Margaret van Heek; Joyce J Hwa
Journal:  Eur J Pharmacol       Date:  2008-02-12       Impact factor: 4.432

View more
  53 in total

Review 1.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

2.  Nonalcoholic fatty liver disease: from lipid profile to treatment.

Authors:  Kouichi Miura; Hirohide Ohnishi
Journal:  Clin J Gastroenterol       Date:  2012-06-17

Review 3.  Role of the gut in lipid homeostasis.

Authors:  Nada A Abumrad; Nicholas O Davidson
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

Review 4.  Role of the gut in modulating lipoprotein metabolism.

Authors:  Alan A Hennessy; R Paul Ross; Gerald F Fitzgerald; Noel Caplice; Catherine Stanton
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

5.  Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans.

Authors:  Xiaobo Lin; Susan B Racette; Michael Lefevre; Lina Ma; Catherine Anderson Spearie; Karen Steger-May; Richard E Ostlund
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

6.  Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.

Authors:  George N Ioannou; Derrick M Van Rooyen; Christopher Savard; W Geoffrey Haigh; Matthew M Yeh; Narci C Teoh; Geoffrey C Farrell
Journal:  J Lipid Res       Date:  2014-12-17       Impact factor: 5.922

Review 7.  Cell cholesterol homeostasis: mediation by active cholesterol.

Authors:  Theodore L Steck; Yvonne Lange
Journal:  Trends Cell Biol       Date:  2010-09-16       Impact factor: 20.808

8.  Mechanisms of Niemann-Pick type C1 Like 1 protein degradation in intestinal epithelial cells.

Authors:  Pooja Malhotra; Vinay Soni; Yoshihide Yamanashi; Tappei Takada; Hiroshi Suzuki; Ravinder K Gill; Seema Saksena; Pradeep K Dudeja; Waddah A Alrefai
Journal:  Am J Physiol Cell Physiol       Date:  2019-02-21       Impact factor: 4.249

Review 9.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

Review 10.  Antilipidemic Drug Therapy Today and in the Future.

Authors:  Werner Kramer
Journal:  Handb Exp Pharmacol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.